62421-54-9

Basic information

• Product Name: 1,2-NAPHTHALENEDIOL, 6-(DIPROPYLAMINO)-5,6,7,8-TETRAHYDRO-, HYDROBROMIDE
• Synonyms: 1,2-NAPHTHALENEDIOL, 6-(DIPROPYLAMINO)-5,6,7,8-TETRAHYDRO-, HYDROBROMIDE;1,2-Naphthalenediol, 6-(dipropylamino)-5,6,7,8-tetrahydro-, hydr;TL 102 hydrobromide
• CAS NO: 62421-54-9
• Molecular Formula: C16H26BrNO2
• Molecular Weight: 344.28714
• Mol File: 62421-54-9.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1,2-NAPHTHALENEDIOL, 6-(DIPROPYLAMINO)-5,6,7,8-TETRAHYDRO-, HYDROBROMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2-NAPHTHALENEDIOL, 6-(DIPROPYLAMINO)-5,6,7,8-TETRAHYDRO-, HYDROBROMIDE(62421-54-9)
• EPA Substance Registry System: 1,2-NAPHTHALENEDIOL, 6-(DIPROPYLAMINO)-5,6,7,8-TETRAHYDRO-, HYDROBROMIDE(62421-54-9)

Safety Data

• Hazardous Substances Data: 62421-54-9(Hazardous Substances Data)

Usage

Chemical structure

A naphthalene ring with two hydroxyl groups and a dipropylamino group attached to it.

Hydrobromide form

Indicates the presence of a bromine ion in the compound.

Research and pharmaceutical applications

Commonly used as a reagent or intermediate in the synthesis of various organic compounds.

Potential therapeutic properties

May have potential therapeutic properties, but further studies and testing are required to confirm its specific uses and effects.

Safety precautions

It is important to handle this chemical with proper safety precautions and in accordance with relevant regulations and guidelines.

Upstream product

• 58352-86-6 (+/-)-5,6-dimethoxy-2-(N,N-di-n-propylamino)tetralin 
• 58352-86-6 (-)-5,6-dimethoxy-2-(N,N-di-n-propylamino)tetralin 
• 58352-86-6 (+)-5,6-dimethoxy-2-(N,N-di-n-propylamino)tetralin 

Relevant articles and documents

Resolution of 5,6-Dihydroxy-2-(N,N-di-n-propylamino)tetralin in Relation to the Structural and Stereochemical Requirements for Centrally Acting Dopamine Agonists

The enantiomers of 5,6-dimethoxy-2-(N,N-dipropylamino)tetralin were prepared with use of (+)- and (-)-dibenzoyltartaric acid as the resolving agent.Ether cleavage with BBr3 gave the enantiomers of the dihydroxy compound 5,6-dihydroxy-2-(N,N-dipropylamino)tetralin (5,6-(OH)2-DPATN).The in vitro activities of (+)- and (-)-5,6-(OH)2-DPATN were evaluated in binding studies with rat striatal tissue with use of -N-n-propylnorapomorphine (NPA) as the ligand.IC50 (nM) values for (-)- and (+)-5,6-(OH)2-DPATN were 2.5 and 400, respectively.The in vivo efficacy of the enantiomers was evaluated by examining their effects on the metabolism of dopamine in rat striatum.After a 0.5 μmol/kg ip injection of the (-) enantiomer, the concentrations of the metabolites HVA and DOPAC were reduced to 50percent of control values, whereas at this dose the (+) isomer was inactive.On the basis of these findings together with the stereochemical data of previously described DA agonists, a dopamine-receptor model has been developed which consists of two binding sites for the amine nitrogen of DA agonists in addition to a major binding site for the m-hydroxy group.The relevance of this model with its accessory features is discussed in relation to the structure and pharmacological data of different DA agonists.